STI Knowledge and HPV Vaccine Acceptance in Bamako, Mali in 2012

HPV Clinical Trial

Official title:

Knowledge, Attitudes, Practices and Willingness to Vaccinate in Preparation for the Introduction of HPV Vaccines in Bamako, Mali

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT05767138
• Other study ID #: HPV Vaccine Survey
• Status: Completed
• Start date: March 2011
• Est. completion date: June 2011

Study information

• Verified date: March 2023
• Source: Global Alliance to Immunize Against AIDS Vaccine Foundation
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

Although screening for pre-cancerous cervical lesions and human papilloma virus (HPV) vaccination are accepted and effective means to prevent cervical cancer, women in Mali have limited access to these interventions. In addition, cervical cancer prevention by HPV vaccination has been controversial in some settings. To reduce cervical cancer prevalence and increase HPV vaccine uptake, it is important to understand the level of knowledge about cervical cancer screening and practices related to vaccination in at-risk populations. In this study, the level of knowledge about HPV and cervical cancer and attitudes towards vaccination were assessed among 301 participants (male and female, adults and adolescents) in a house-to-house survey in two urban neighborhoods in Bamako, Mali. The survey was combined with a brief educational session on HPV. Prior to the education session, overall knowledge of HPV infection and cervical cancer was very low: only 8% knew that HPV is a sexually transmitted infection (STI). Less than 20% of women had ever consulted a gynecologist and less than 3% had ever had cervical cancer screening. After hearing a description of HPV vaccine, more than 80% would accept HPV vaccination; fathers and husbands were identified as primary decisions makers and local clinics or the home as preferred sites for vaccination. This study provides information on STI knowledge and vaccine acceptance in Bamako, Mali in 2012, prior to the introduction of HPV vaccination.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 301
• Est. completion date: June 2011
• Est. primary completion date: May 2011
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 12 Years and older

Eligibility

Inclusion Criteria:

• 12-17 years of age, with guardian consent

• 18 years or older

• Male or Female

• Living in Mèkin-Sikoro and Djikoroni

Exclusion Criteria:

• 12-17 years of age, without guardian consent

• <12 years of age

• Living outside Mèkin-Sikoro and Djikoroni

Related Conditions & MeSH terms

• HPV
• HPV-Related Cervical Carcinoma

Intervention

Behavioral:
• HPV Vaccine Acceptance Survey

Locations

Country	Name	City	State
n/a

Sponsors (2)

Lead Sponsor	Collaborator
Global Alliance to Immunize Against AIDS Vaccine Foundation	Merck Sharp & Dohme LLC

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Participants' acceptance of the vaccine	Number of participants willing to be vaccinated against HPV and their vaccination preferences after educational sessions	immediately after the intervention
Secondary	Knowledge of STIs, HPV, and Cervical Cancer	Knowledge Question asked before and after educational session	immediately after the intervention